What Prevents Chemo-Linked HFS? - Summary - MDSpire

What Prevents Chemo-Linked HFS?

Network meta-analysis compares preventive agents for chemotherapy-induced hand-foot syndrome

  • By

  • Jess Allerton

  • March 5, 2026

  • 3 min

Share

Objective:

To evaluate pharmacologic strategies for preventing chemotherapy-induced hand-foot syndrome (HFS).

Key Findings:
  • Silymarin's findings were based on a small trial, indicating the need for caution in interpreting its effectiveness.
Interpretation:

Diclofenac is the most consistently supported intervention for preventing HFS, but findings for silymarin require further validation.

Limitations:
  • Small sample sizes in several studies may limit the reliability of findings.
  • Variability in HFS grading systems across trials affects comparability and interpretation.
Conclusion:

Larger randomized trials are needed to confirm the effectiveness of silymarin, while diclofenac shows promise as a preventive strategy for HFS.

Original Source(s)

What Prevents Chemo-Linked HFS?

  • by Jess Allerton

  • March 5, 2026

Related Content

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Investigation of Lactylation-Associated Genes and Their Relationship with the Development of Diabetic Foot Ulcers and Immune Cell Infiltration